Volume analysis examines how the number of traded shares affects a security's price. Discover how this method is integral to ...
Dutch start-up VectorY Therapeutics has been given the green light by the FDA for a phase 1/2 trial of a drug against a target implicated in up to 97% of amyotrophic lateral sclerosis (ALS) cases. VTx ...
This study presents SynaptoGen, a differentiable extension of connectome models that links gene expression, protein-protein interaction probabilities, synaptic multiplicity, and synaptic weights, and ...
What would a Tesla be without controversy and split opinions? The Tesla Model Y’s midcycle refresh brought significant enough changes to earn it a spot in our 2026 SUV of the Year competition. The ...
There was a time when the Tesla Model Y made the most sense for EV shoppers. When it arrived for 2020, the SUV offered compelling range and charging speeds, a spacious cabin, and a tablet-like ...
The search for an unknown planet in our solar system has inspired astronomers for more than a century. Now, a recent study suggests a potential new candidate, which the paper’s authors have dubbed ...
VectorY Therapeutics has seen the shape of things to come—and it involves finding fresh ways to deliver its gene therapies into the brain. The Dutch biotech has secured an exclusive option to evaluate ...
AMSTERDAM & BOSTON & SEATTLE--(BUSINESS WIRE)--VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, and ...
It’s hard to fathom this happening today, but not so long ago, we’d collectively get really, really excited about the debut of a new iPhone. Livestreams broke the internet, Apple Stores overflowed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback